ReviewEuropean heart journal2025
Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine.
Review in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis.Clinical pharmacokinetics · 2026Trial
- ACO-SWITCH: Rationale and Design of a Phase 4 Study Evaluating Serum Transthyretin in ATTR-CM After Switching from Tafamidis to Acoramidis.Cardiology and therapy · 2026Article
- Rationale and Design of ACO-REAL: A Real-World Non-Interventional Study of Acoramidis in Routine Clinical Practice.Cardiology and therapy · 2026Article
- Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy.Circulation. Cardiovascular imaging · 2026Article
- Human iPSC-derived 3D cardiac models for cardiomyopathies: organoids, spheroids, and engineered heart tissues as translational platforms.Stem cells (Dayton, Ohio) · 2026Review
- Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial.Nature medicine · 2026Article
- Heart failure in the elderly: epidemiology, mechanisms, and management.European heart journal · 2026Review
- Early timepointEJNMMI research · 2026Article
- Evaluation of the Current ATTR-CM Treatment Landscape via a Mathematical Model of TTR Dissociation and Amyloid Formation.CPT: pharmacometrics & systems pharmacology · 2026Article
- Article
- Current treatment decisions in cardiac transthyretin amyloidosis: a multicentre analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- [Update on hypertrophic cardiomyopathy].Innere Medizin (Heidelberg, Germany) · 2026Review
- Structures of dye-bound transthyretin amyloid fibrils from abdominal fat biopsies.Nature communications · 2026Article
- Application of Omics Analysis in the Clinical Practice and Research of Transthyretin Amyloidosis.Genes · 2026Review
- Multidisciplinary Approaches for Diagnosing Underrecognized Transthyretin Amyloidosis in Real-World Practice.Acta Cardiologica Sinica · 2026Article
- Wild-type transthyretin cardiac amyloidosis: the journey to diagnosis in the Czech Republic : The research project of the Czech Society of Cardiology.Orphanet journal of rare diseases · 2026Article
- Article
- Phenomenological model of transthyretin stabilization.Scientific reports · 2026Article
- Multiple Red Flags of Transthyretin Amyloid Cardiomyopathy in a Single Patient: A Case Report on Diagnostic Challenge.International medical case reports journal · 2026Article
- Hereditary transthyretin amyloid cardiomyopathy caused by the rare TTR p.Ser43Asn variant in an Asian family: a case report.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
Development of specific therapies addressing the underlying diseases' mechanisms constitutes the basis of precision medicine. Transthyretin cardiac amyloidosis (ATTR-CM) is an exemplar of precise therapeutic approach in the field of heart failure and cardiomyopathies. A better understanding of the underlying pathophysiology, more precise data of its epidemiology, and advances in imaging techniques that allow non-invasive diagnosis have fostered the development of new and very effective specific therapies for ATTR-CM. Therapeutic advances have revolutionized the field, transforming a rare, devastating, and untreatable disease into a more common disease with several therapeutic alternatives available. Three main types of therapies (stabilizers, suppressors, and degraders) that act at different points of the amyloidogenic cascade have been developed or are currently under investigation. In this review, the key advances in pathophysiology and epidemiology that have occurred in the last decades along with the different therapeutic alternatives available or under development for ATTR-CM are described, illustrating the role of precision medicine applied to cardiovascular disorders. Pending questions that would need to be answered in upcoming years are also reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.